| Name | Title | Contact Details |
|---|
WISH Center, The is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Luke's Hospital & Health Network is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Bethlehem, PA. To find more information about St. Luke's Hospital & Health Network, please visit www.slhn.org
We are a Louisville-based healthcare holdings company with physical therapy partners in over 530+ clinics across 29 states. Confluent Health transforms physical health by effectively meeting the needs of the communities we serve: patients, employers, payors, students, and providers. Primarily focusing on physical and occupational therapy, which provides long-lasting outcomes without surgery, medication, or diagnostic imaging, Confluent Health companies aid in reducing healthcare expenditures and increasing overall population health. Our companies focus on the following services: * Outpatient Physical and Occupational Therapy * Workplace Injury Prevention Through Early Intervention and Employee Screening * Advanced and Entry-Level Education for Physical Therapists and Occupational Therapists No matter what clinic you`re at or where you`re being seen, we have one goal - to get you back to your life, faster.
Kindful Health is a company that provides hospice, palliative, and virtual care services to those enduring a serious illness and those who choose symptom management and pain relief as end of life care.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.